- Home
- ECO vs KALV Comparison
ECO vs KALV Comparison
Compare ECO & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECO
- KALV
- Stock Information
- Founded
- ECO 2018
- KALV N/A
- Country
- ECO Greece
- KALV United States
- Employees
- ECO N/A
- KALV N/A
- Industry
- ECO
- KALV Biotechnology: Pharmaceutical Preparations
- Sector
- ECO
- KALV Health Care
- Exchange
- ECO Nasdaq
- KALV Nasdaq
- Market Cap
- ECO 878.3M
- KALV 796.4M
- IPO Year
- ECO N/A
- KALV N/A
- Fundamental
- Price
- ECO $28.29
- KALV $10.97
- Analyst Decision
- ECO Strong Buy
- KALV Strong Buy
- Analyst Count
- ECO 2
- KALV 8
- Target Price
- ECO $34.50
- KALV $26.43
- AVG Volume (30 Days)
- ECO 137.2K
- KALV 1.5M
- Earning Date
- ECO 11-07-2025
- KALV 09-11-2025
- Dividend Yield
- ECO 6.43%
- KALV N/A
- EPS Growth
- ECO N/A
- KALV N/A
- EPS
- ECO 2.09
- KALV N/A
- Revenue
- ECO $344,213,634.00
- KALV $1,426,000.00
- Revenue This Year
- ECO N/A
- KALV N/A
- Revenue Next Year
- ECO $10.10
- KALV $213.43
- P/E Ratio
- ECO $13.55
- KALV N/A
- Revenue Growth
- ECO N/A
- KALV N/A
- 52 Week Low
- ECO $17.91
- KALV $7.30
- 52 Week High
- ECO $35.64
- KALV $17.28
- Technical
- Relative Strength Index (RSI)
- ECO 46.45
- KALV 32.68
- Support Level
- ECO $28.34
- KALV $11.93
- Resistance Level
- ECO $29.55
- KALV $12.04
- Average True Range (ATR)
- ECO 0.62
- KALV 0.56
- MACD
- ECO -0.28
- KALV -0.21
- Stochastic Oscillator
- ECO 18.71
- KALV 10.10
About ECO Okeanis Eco Tankers Corp.
Okeanis Eco Tankers Corp owns and operates tanker vessels in Greece. The business of the company is to own, charter out, and operate tanker vessels. The company owns, through its vessel-owning subsidiaries, a fleet of around seven tanker vessels and has around eight tanker vessels on order. The sailing fleet consists of around six modern Suezmax tankers and eight VLCC tankers.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.